Skip to main content
    S

    Senseonics Holdings, Inc. Common Stock (SENS)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $10.90
    +0.32 (+3.02%)

    Market Cap: $579.58M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Senseonics Holdings, Inc. Common Stock (SENS) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Senseonics Holdings, Inc. Common Stock (SENS) is confirmed to report earnings on Mar 1, 2027, after the close. In the quarter ended Sep 30, 2026, Senseonics Holdings, Inc. Common Stock reported EPS of -$0.50, below the -$0.49 estimate. It beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    31%(12/39)
    Avg Surprise
    +2.93%

    Upcoming Estimates

    Reports Mar 1, 2027 after closePeriod ending Dec 31, 2026
    EPS Consensus-$0.42
    Range-$0.53 - -$0.38
    10 analysts
    Revenue Consensus
    $23.91M
    Range$22.34M - $25.09M
    9 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.52
    Range-$0.57 - -$0.47
    4 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.56+7.0%
    60d ago-$0.56+7.0%
    30d ago-$0.55+6.8%
    7d ago-$0.55+6.8%
    Current-$0.52
    Revenue Consensus
    $17.93M
    Range$16.10M - $20.34M
    4 analysts

    Next Report

    SENS has a confirmed report date of Mar 1, 2027, after the close.

    SENS Earnings Call

    The latest SENS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, SENS beat 12, missed 24 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $19.56M, up 141.5% from $8.10M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.50-$0.49-$0.64 - -$0.41-2.04%MissN/A72 up, 0 downNov 9, 2026$19.56M
    Jun 30, 2026-$0.63-$0.55-$0.73 - -$0.50-14.55%MissN/A65 up, 1 downAug 6, 2026$14.48M
    Mar 31, 2026-$0.71-$0.70-$0.74 - -$0.62-1.43%MissN/A71 up, 6 downMay 7, 2026$11.71M
    Dec 31, 2025-$0.46-$0.02N/AN/AN/AN/A71 up, 0 downMar 2, 2026$14.26M
    Sep 30, 2025-$0.43-$0.33N/A-30.30%MissN/A52 up, 0 downNov 5, 2025$8.10M
    Jun 30, 2025-$0.40-$0.40-$0.40 - -$0.400.00%In lineN/A62 up, 0 downAug 6, 2025$6.65M
    Mar 31, 2025-$0.40-$0.47-$0.60 - -$0.40+14.89%BeatN/A32 up, 0 downMay 8, 2025$6.26M
    Dec 31, 2024-$0.02-$0.03-$0.03 - -$0.03+33.33%BeatN/A20 up, 1 downMar 3, 2025$8.30M
    Sep 30, 2024-$0.80-$0.70-$0.80 - -$0.60-14.29%MissN/A50 up, 0 downNov 7, 2024$4.26M
    Jun 30, 2024-$0.66-$0.60-$0.60 - -$0.60-10.00%MissN/A40 up, 0 downAug 8, 2024$4.87M
    Mar 31, 2024-$0.60-$0.60-$0.60 - -$0.600.00%In lineN/A30 up, 0 downMay 13, 2024$5.05M
    Dec 31, 2023-$0.03-$0.04-$0.05 - -$0.04+25.00%Beat-250.0%30 up, 0 downFeb 29, 2024$8.03M
    Sep 30, 2023-$0.95-$0.70-$0.80 - -$0.60-35.71%MissN/A40 up, 0 downNov 9, 2023$6.10M
    Jun 30, 2023-$0.71-$0.60-$1.00 - -$0.60-18.33%MissN/A40 up, 0 downAug 10, 2023$4.13M
    Mar 31, 2023-$0.93-$0.73-$0.80 - -$0.60-27.40%MissN/A30 up, 0 downMay 9, 2023$4.14M
    Dec 31, 2022$0.02-$0.04N/A+150.00%Beat-90.5%N/A0 up, 0 downMar 15, 2023$5.57M
    Sep 30, 2022-$2.60-$0.85N/A-205.88%MissN/AN/A0 up, 0 downNov 8, 2022$4.62M
    Jun 30, 2022-$0.92-$0.73N/A-26.03%MissN/AN/A0 up, 0 downAug 9, 2022$3.71M
    Mar 31, 2022-$0.65-$0.73-$0.80 - -$0.40+10.96%BeatN/A40 up, 0 downMay 10, 2022$2.48M
    Dec 31, 2021$0.21-$0.03-$0.04 - -$0.01+800.00%BeatN/A60 up, 0 downMar 1, 2022$4.01M
    Sep 30, 2021-$0.68-$1.28-$2.60 - -$0.60+46.88%BeatN/A7N/ANov 9, 2021$3.53M
    Jun 30, 2021-$0.91-$0.48-$1.00 - $1.00-89.58%MissN/A6N/AAug 9, 2021$3.29M
    Mar 31, 2021-$0.84-$0.84-$1.60 - -$0.800.00%In lineN/A6N/AMay 13, 2021$2.85M
    Dec 31, 2020-$0.44-$0.09-$0.23 - -$0.05-388.89%MissN/A6N/AMar 4, 2021$3.88M
    Sep 30, 2020-$1.47-$1.33-$1.60 - -$0.80-10.53%MissN/A6N/ANov 9, 2020$767000
    Jun 30, 2020-$1.49-$1.96-$2.40 - -$1.00+23.98%BeatN/A6N/AAug 10, 2020$261000
    Mar 31, 2020-$0.19-$0.13-$0.18 - -$0.04-46.15%MissN/A8N/AJun 9, 2020$36000
    Dec 31, 2019-$3.85-$3.23-$4.20 - -$2.40-19.20%MissN/A9N/AMar 12, 2020$8.95M
    Sep 30, 2019-$3.54-$3.20-$4.00 - -$2.60-10.63%MissN/A10N/ANov 12, 2019$4.32M
    Jun 30, 2019-$3.40-$3.28-$3.40 - -$2.80-3.66%MissN/A9N/AAug 7, 2019$4.61M
    Mar 31, 2019-$3.40-$2.73-$3.40 - -$1.20-24.54%MissN/A9N/AMay 9, 2019$3.42M
    Dec 31, 2018-$0.03-$0.14-$0.20 - -$0.12+78.57%BeatN/A9N/AMar 12, 2019$7.19M
    Sep 30, 2018-$2.80-$2.66-$3.40 - -$2.40-5.26%MissN/A6N/ANov 8, 2018$5.16M
    Jun 30, 2018-$4.60-$2.72-$3.00 - -$2.40-69.12%MissN/A6N/AAug 8, 2018$3.62M
    Mar 31, 2018-$3.20-$2.40-$2.80 - -$2.00-33.33%MissN/A5N/AMay 10, 2018$2.95M
    Dec 31, 2017-$0.12-$0.13-$0.15 - -$0.11+7.69%BeatN/A4N/AMar 13, 2018$2.91M
    Sep 30, 2017-$2.60-$2.55-$3.20 - -$2.20-1.96%MissN/A4N/AOct 31, 2017$2.10M
    Jun 30, 2017-$2.40-$2.65-$3.00 - -$2.00+9.43%BeatN/A4N/AAug 9, 2017$814000
    Mar 31, 2017-$2.80-$2.45N/A-14.29%MissN/AN/AN/AMay 4, 2017$553000
    Dec 31, 2016-$0.10-$0.12N/A+16.67%BeatN/AN/AN/AFeb 23, 2017$276000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.69, after -$2.08 the year before. It was -$8.10 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.69N/A
    Dec 31, 2024-$2.08N/A
    Dec 31, 2023-$2.62N/A
    Dec 31, 2022-$4.15N/A
    Dec 31, 2021-$2.22N/A
    Dec 31, 2020-$3.59N/A
    Dec 31, 2019-$14.19N/A
    Dec 31, 2018-$10.63N/A
    Dec 31, 2017-$7.92N/A
    Dec 31, 2016-$8.10N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,100 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,12611
    2026Q1Mar 31, 20265,57111
    2025Q4Dec 31, 20257,19812
    2025Q3Sep 30, 20256,34612
    2025Q2Jun 30, 20255,1979
    2025Q1Mar 31, 20254,0246
    2024Q3Sep 30, 20242,8546
    2024Q2Jun 30, 20243,5046

    2026Q3 Earnings Call

    Opening remarks

    Jeremy Feffer Investor Relations Representative Thank you. This is Jeremy Feffer from LifeSci Advisors. Before we begin today, let me remind you that the company's remarks include forward-looking statements. These statements reflect management's expectations about future events, operating plans, regulatory matters, product enhancements, company performance, and other matters, and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties. A list of the factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is detailed under Risk Factors and elsewhere in our annual report on Form 10-K for the year ended December 31, 2025, our 10-Q for the period ended September 30, 2026, and our other reports filed with the SEC. These documents are available on the Investor Relations section of our website at www.senseonics.com. We undertake no obligation to update publicly or revise these forward-looking statements for any reason, except as required by law. Joining me today from Senseonics are Tim Goodnow, President and Chief Executive Officer; Brian Hansen, Chief Commercial Officer; and Rick Sullivan, Chief Financial Officer. Mukul Jain, Chief Operating Officer, will also be available during the Q&A. And now I'd like to turn the call over to Tim.

    Tim Goodnow President and Chief Executive Officer Thanks, Jeremy, and good afternoon, everyone. Q3 was a breakout quarter for Senseonics. Revenue reached $19.6 million, up about 140%, well more than double the prior year. It's the highest in our history and the second quarter in a row in which we have set a new mark. This is driven by a record number of new patient starts. In the U.S., revenue grew about 160% to $16.8 million. And outside the U.S., it rose about 65% to $2.8 million. Our sales are running ahead of our earlier expectations, and we are now raising full-year revenue guidance for the third time this year. We are now projecting $68 million to $70 million of full-year revenue, from our prior range of $62 million to $66 million. What's driving this? First and foremost, the product. Eversense 365 is the only CGM that delivers a full year on a single sensor with exceptional accuracy throughout and a removable transmitter that is easy on the skin. Patients feel the difference, and retention is exceeding our plan. Our execution is amplifying these advantages, and our commercial team is performing superbly. Together, we're making Eversense easier to get. Our insertion network keeps widening, reimbursement is improving, and our integration partnerships are growing. Those are the priorities we set at the start of the year, and each one is delivering. Just as telling is where our new patients are coming from: the overwhelming majority are switching from other CGMs.

    Frequently Asked Questions About SENS

    When is Senseonics Holdings, Inc. Common Stock's next earnings date?

    Senseonics Holdings, Inc. Common Stock's next earnings report is confirmed for Mar 1, 2027, after the close.

    Did SENS beat earnings estimates last quarter?

    No. Senseonics Holdings, Inc. Common Stock reported EPS of -$0.50 for the quarter ended Sep 30, 2026, below the -$0.49 estimate by 2.04%.

    What EPS do analysts expect from SENS next quarter?

    The consensus EPS estimate for Senseonics Holdings, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.42 from 10 analysts, with estimates from -$0.53 to -$0.38.

    How often does SENS beat earnings estimates?

    Senseonics Holdings, Inc. Common Stock beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate, with an average surprise of -1.80%.

    Does SENS report before or after the market opens?

    Senseonics Holdings, Inc. Common Stock is confirmed to report on Mar 1, 2027, after the market closes.